StagePIPE | IPO
About Vivani Medical
Vivani Medical (Nasdaq: VANI) leverages proprietary technologies to develop and commercialize drug and device implants that treat patients with chronic diseases with high unmet medical needs. The Drug Implant division is developing a new portfolio of miniature drug implants which utilize its proprietary NanoPortal drug implant technology. These drug implants, designed to deliver minimally fluctuating drug profiles, will address drug non-adherence which is a leading reason for sub-optimal clinical benefit associated with oral and injectable products that treat chronic diseases. The company’s lead product, NPM-119, is a GLP-1 receptor agonist under development to treat patients with Type 2 diabetes. The company was formerly known as Second Sight Medical Products and rebranded to Vivani Medical in August 2022 after its merger with Nano Precision Medical. Vivani Medical was founded in 1998 and is based in Sylmar, California. In November 2014, Vivani Medical went public with a valuation of $311M.
Missing: Vivani Medical's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Vivani Medical's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Vivani Medical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Vivani Medical is included in 1 Expert Collection, including Digital Health.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Vivani Medical Patents
Vivani Medical has filed 333 patents.
The 3 most popular patent topics include:
- Implants (medicine)
Implants (medicine), Neurotechnology, Capacitors, Semiconductor device fabrication, Neurophysiology
Implants (medicine), Neurotechnology, Capacitors, Semiconductor device fabrication, Neurophysiology
Latest Vivani Medical News
May 17, 2023
05/17/2023 | 04:38pm EDT Message : Disclaimers The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking statements." These statements may be identified by words such as "estimates," "anticipates," "projects," "plans" or "planned," "strategy," "goal," "seeks," "may," "will," "expects," "intends," "believes," "should," and similar expressions, or the negative versions thereof, and which also may be identified by their context. All statements that address operating performance or events or developments that Vivani Medical, Inc. ("Vivani", the "Company", "we" or "us) expects or anticipates will occur in the future, such as stated objectives or goals, our products and their therapeutic potential and planned development, the indications that we intend to target, our technology, our business and strategy, milestones, addressable markets, or that are not otherwise historical facts, are forward-looking statements. While management has based any forward-looking statements included in this presentation on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements as a result of various factors. These risks and uncertainties include, but are not limited to, that we may fail to complete any required pre-clinical activities for NPM-119 or otherwise commence our planned Phase 2 trial for this product under development; conduct any pre-clinical activities of our other products; our products may not demonstrate safety or efficacy in clinical trials; we may fail to secure marketing approvals for our products; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our products may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks and uncertainties are described in our Annual Report on Form 10-K filed on March 31, 2023, and our subsequent filings with the SEC. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto, or any change in events, conditions, or circumstances on which any such statement is based. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third party sources and the Company's own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. All of our therapies are still investigational and have not been approved by any regulatory authority for any use. 2 PhD Bioengineering (UCSF/UC Berkeley) Research focused on diabetes treatment Formerly at Boston Scientific and Minimed Truc Le, MBA - Chief Operations Officer Brigid Makes MBA - Chief Financial Officer •
Vivani Medical Frequently Asked Questions (FAQ)
When was Vivani Medical founded?
Vivani Medical was founded in 1998.
Where is Vivani Medical's headquarters?
Vivani Medical's headquarters is located at 13170 Telfair Avenue, Sylmar.
What is Vivani Medical's latest funding round?
Vivani Medical's latest funding round is PIPE.
How much did Vivani Medical raise?
Vivani Medical raised a total of $34.9M.
Who are the investors of Vivani Medical?
Investors of Vivani Medical include Gregg Williams, Versant Ventures and Emergent Medical Partners.
Who are Vivani Medical's competitors?
Competitors of Vivani Medical include AcuFocus, EyeTechCare, AqueSys, Triangle Biosystems, SpinalMotion and 12 more.
Compare Vivani Medical to Competitors
NovaLign Orthopaedics, formerly known as OsteoLign, is developing a minimally invasive solution for long bone fractures.
Beta-Stim - Minimally invasive implantable neuro-stimulator to treat obesity and type II diabetic patients.
EyeTechCare is developing non-invasive therapeutic medical devices for the ophthalmology market based on High-Intensity Focused Ultrasound (HIFU), a technology that allows ambulatory and rapid treatment to be performed, thereby limiting the cost and the risk to the patient. The company's first device, EyeOP1 (R), for the treatment of glaucoma, has been undergoing clinical trials in France and Europe.
Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.
Urovalve, Inc. has developed and patented technology to control fluid flow through small diameter flexible tubing. The core technology for the Surinate bladder management system is comprised of a magnetically controlled valve that can be activated remotely by a Surinate wearer who uses a hand held magnet to self-regulate flow. Currently available devices require continuous bladder drainage or insertion of a tube into the urethra several times each day. The Surinate bladder management system aims to provide a solution to the problems of life style, urinary tract infections, and substantial healthcare worker expenses associated with existing catheters.
IntraTherm is focused on continuous improvement of the medical device industry through the introduction of processes and products that aid surgeons and patients in their fight against cancer. The company's product is designed to complement surgery by sterilizing the site of surgery via a controllable and predictable thermal ablation device, with less than minimal short term, and without long term side effects.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.